A Discussion of Pharmacoeconomics Applied to Blood Substitutes

  • Pamela Bassett


Pharmacoeconomics examines the costs and the consequences of health interventions. The results of pharmacoeconomic studies provide the economic reasons to use a particular product based on direct comparisons of costs and outcomes of competing products or interventions. In today’s healthcare marketplace, providers, and specifically managed care organizations (MCOs), are forced to make difficult choices about which products will be made available for use in their organizations. It is now imperative to make pharmacoeconomic study results available to decision makers for review in order to achieve product acceptance for use in most organizations (Clifton and Blumenschein 1995). Without the results of a pharmacoeconomic study at product launch, the likelihood of product use and acceptance in today’s market is extremely low. Therefore, implementing pharmacoeconomic studies during clinical trials is recommended.


Price Strategy Health Utility Index Pharmacoeconomic Study Blood Substitute Product Launch 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bloom, B.S., and A.M. Fendrick. Timing and timeliness in medical care evaluation. PharmacoEconomics 9: 183–187, 1996.PubMedCrossRefGoogle Scholar
  2. Clemens, K., R. Townsend, F. Luscombe, J. Mauskopf, J. Osterhaus, and J. Bobula. Methodological and conduct principles for pharmacoeconomic research. PharmacoEconomics 8: 169–174, 1995.PubMedCrossRefGoogle Scholar
  3. Clifton, G.D., and K. Blumenschein. The use of pharmaceuticals in critical care, the importance of outcome prediction models. PharmacoEconomics 7: 388–392, 1995.PubMedCrossRefGoogle Scholar
  4. Coyle, D. Statistical analysis in pharmacoeconomic studies. PharmacoEconomics 9: 506–516, 1996.PubMedCrossRefGoogle Scholar
  5. Drummond, M., and L. Davies. Economic analysis alongside clinical trials: revisiting the methodological issues. International Journal of Technology Assessment in Health Care 7: 561–573, 1991.PubMedCrossRefGoogle Scholar
  6. Drummond, M.F., and G.L. Stoddart. Economic analysis and clinical trials. Controlled Clinical Trials 5: 115–128, 1984.PubMedCrossRefGoogle Scholar
  7. Eisenberg, J., H. Glick, K. Schulman et al. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Pharmcoepidemiology, 2nd ed. (B. Strom, ed.). Chichester: John Wiley and Sons Ltd., 1994.Google Scholar
  8. Feeny, D., W. Furlong, M. Boyle, and G.W. Torrance. Multiattribute health status classification systems, health utilities index. PharmacoEconomics 7: 490–502, 1996.CrossRefGoogle Scholar
  9. Hillman, A.L., and M.S. Kim. Economic decision making in healthcare, a standard approach to discounting health outcomes. PharmacoEconomics 7: 198–205, 1995.PubMedCrossRefGoogle Scholar
  10. Johannesson, M. Economic evaluation of drugs and its potential uses in policy making. PharmacoEconomics 8: 190–198, 1995.PubMedCrossRefGoogle Scholar
  11. Mauskopf, J., K. Schulman, L. Bell, and H. Glick. A strategy for collecting pharmacoeconomic data during Phase II/III clinical trials. PharmacoEconomics 9: 264–277, 1996.PubMedCrossRefGoogle Scholar
  12. Rutten-van Molken, M., E. van Doorslaer, and R. van Vliet. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Economics 3: 333–345, 1994.CrossRefGoogle Scholar
  13. Santell, J.P. Projecting future drug expenditures - 1996. American Journal of Health-System Pharmacists 53: 139–150, 1996.Google Scholar
  14. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: a report on principles. Annals of Internal Medicine 122: 61–70, 1995.Google Scholar
  15. Torrance, G.W., D. Blaker, A. Detsky, W. Kennedy, F. Schubert, D. Menon, P. Tugwell, R. Konchak, E. Hubbard, and T. Firestone. Canadian guidelines for economic evaluation of pharmaceuticals. PharmacoEconomics 9: 535–559, 1996.PubMedCrossRefGoogle Scholar
  16. Torrance, G.W., W. Furlong, D. Feeny, and M. Boyle. Multi-attribute preference functions, health utilities index. PharmacoEconomics 7: 503–520, 1995.PubMedCrossRefGoogle Scholar
  17. Wanke, L.A., and G.M. Ryan. Strategic planning for applied pharmacoeconomics programs. Pharmacy Practice Management Quarterly 1 5: 64–74, 1996.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Pamela Bassett

There are no affiliations available

Personalised recommendations